- Home
- NCV vs GOSS Comparison
NCV vs GOSS Comparison
Compare NCV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- GOSS
- Stock Information
- Founded
- NCV 2003
- GOSS 2015
- Country
- NCV United States
- GOSS United States
- Employees
- NCV N/A
- GOSS N/A
- Industry
- NCV Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- GOSS Health Care
- Exchange
- NCV Nasdaq
- GOSS Nasdaq
- Market Cap
- NCV 317.4M
- GOSS 262.5M
- IPO Year
- NCV N/A
- GOSS 2019
- Fundamental
- Price
- NCV $14.20
- GOSS $1.25
- Analyst Decision
- NCV
- GOSS Strong Buy
- Analyst Count
- NCV 0
- GOSS 3
- Target Price
- NCV N/A
- GOSS $7.33
- AVG Volume (30 Days)
- NCV 405.1K
- GOSS 2.6M
- Earning Date
- NCV 01-01-0001
- GOSS 08-11-2025
- Dividend Yield
- NCV 12.48%
- GOSS N/A
- EPS Growth
- NCV N/A
- GOSS N/A
- EPS
- NCV N/A
- GOSS N/A
- Revenue
- NCV N/A
- GOSS $124,590,000.00
- Revenue This Year
- NCV N/A
- GOSS N/A
- Revenue Next Year
- NCV N/A
- GOSS $91.14
- P/E Ratio
- NCV N/A
- GOSS N/A
- Revenue Growth
- NCV N/A
- GOSS N/A
- 52 Week Low
- NCV $2.84
- GOSS $0.66
- 52 Week High
- NCV $3.59
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- NCV 73.43
- GOSS 49.48
- Support Level
- NCV $14.01
- GOSS $1.20
- Resistance Level
- NCV $14.33
- GOSS $1.33
- Average True Range (ATR)
- NCV 0.15
- GOSS 0.10
- MACD
- NCV 0.04
- GOSS -0.02
- Stochastic Oscillator
- NCV 85.23
- GOSS 18.37
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.